Update on Wearable Cardioverter Defibrillator: A Comprehensive Review of Literature
- PMID: 36128416
- PMCID: PMC9451591
- DOI: 10.14740/cr1387
Update on Wearable Cardioverter Defibrillator: A Comprehensive Review of Literature
Abstract
Despite the advancements in the prevention and treatment of cardiovascular diseases, sudden cardiac death (SCD) remains a leading cause of mortality and is accountable for approximately 15% of the total mortality in the USA. The prognosis after sudden cardiac arrest (SCA) varies significantly and depends largely on the underlying etiology and the rapidity and efficiency of resuscitation; however, the outcome remains poor for most of the patients. The main culprits for SCD are coronary heart disease (CHD) and heart failure with reduced ejection fraction (HFrEF). Patients with HFrEF and an ejection fraction (EF) of less than 35% are considered for an implantable cardioverter-defibrillator (ICD) placement if the EF does not improve. A wearable cardioverter defibrillator (WCD) commonly known as a life-vest is sometimes used as a bridging modality until an ICD is implanted. The indication and utility of WCD is still a controversial topic. The purpose of this article is to provide an up-to-date comprehensive review of literature for WCD utilization.
Keywords: Atrial fibrillation; Heart failure; Tachyarrhythmias; Ventricular fibrillation; Ventricular tachycardia.
Copyright 2022, Alsamman et al.
Conflict of interest statement
The authors declare that they do not have a conflict of interest.
Similar articles
-
Multicenter prospective observational study to clarify the current status and clinical outcome in Japanese patients who have an indication for implantable cardioverter defibrillator (ICD) or wearable cardioverter defibrillator (WCD) (TRANSITION JAPAN-ICD/WCD study): Rationale and design of a prospective, multicenter, observational, comparative study.J Arrhythm. 2024 Mar 27;40(3):423-433. doi: 10.1002/joa3.13028. eCollection 2024 Jun. J Arrhythm. 2024. PMID: 38939793 Free PMC article.
-
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007. doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31. J Am Coll Cardiol. 2013. PMID: 23916930
-
Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period.J Clin Med. 2022 Oct 18;11(20):6122. doi: 10.3390/jcm11206122. J Clin Med. 2022. PMID: 36294443 Free PMC article.
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
-
The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?Expert Rev Med Devices. 2016 Jul;13(7):627-32. doi: 10.1080/17434440.2016.1200969. Epub 2016 Jun 27. Expert Rev Med Devices. 2016. PMID: 27333818 Review.
Cited by
-
National Trends in Admissions, Treatments, and Outcomes for Dilated Cardiomyopathy (2016-2021).Med Sci (Basel). 2025 Jun 23;13(3):83. doi: 10.3390/medsci13030083. Med Sci (Basel). 2025. PMID: 40700112 Free PMC article.
-
Prevention of Early Sudden Cardiac Death after Myocardial Infarction Using the Wearable Cardioverter Defibrillator-Results from a Real-World Cohort.J Clin Med. 2023 Jul 31;12(15):5029. doi: 10.3390/jcm12155029. J Clin Med. 2023. PMID: 37568431 Free PMC article.
References
-
- Centers for Disease C, Prevention. State-specific mortality from sudden cardiac death—United States, 1999. MMWR Morb Mortal Wkly Rep. 2002;51(6):123–126. - PubMed
-
- Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ. et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e210–e271. doi: 10.1161/CIR.0000000000000615. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources